Materials and methods for improving immune responses and skin and/or mucosal barrier functions
Inventors
Berkes, Eva A. • Monsul, Nicholas T. • BOEHM, Frederick T.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9706778-B2
Publication Date
2017-07-18
Expiration Date
Abstract
The subject invention provides compositions and methods for treating human dermatological conditions by employing a microbiome-centered treatment approach. Preferred embodiments of the invention provide pharmaceutical and cosmetic compositions, and the methods of using the same, comprising a strain of Lactobacillus fermentum bacterium, or bioactive extracts thereof, derived from human microbiota and capable of growing in biofilm phenotype.
Core Innovation
The invention is directed to microbiome-centered therapeutic and cosmetic compositions and methods for treating dermatological disorders. The compositions use a bioactive Lactobacillus fermentum strain having an Accession No. PTA-122195, grown as a biofilm, and apply whole cells or bioactive biofilm-derived extracts or lysates, including lyophilized or freeze-dried forms.
The bioactive material inhibits pathogenic biofilm growth, adhesion and detachment, while promoting commensal Staphylococcus epidermidis growth. It is used in a manner that modulates microbial dysbiosis associated with skin.
The biofilm-derived bioactives are described as enhancing skin barrier function such as upregulating filaggrin and modulating innate immunity via increased beta-defensins including HBD-1, HBD-2 and HBD-3. The document also mentions IL-1α, IL-4, IL-13, and TSLP in the context of immune modulation and states that the bioactives may act as PPAR agonists including PPAR-alpha, PPAR-beta/delta and PPAR-gamma.
The document reports support using ex vivo human skin models and describes assays and examples comparing protein profiles for biofilm versus planktonic phenotypes, along with quantified antimicrobial and immune-barrier effects. It also states formulation and applicability to skin and mucosal barrier disorders.
Claims Coverage
The partial content contains one independent claim. It includes one core inventive concept focused on inhibiting microbial growth on a surface by applying a microbial growth-inhibiting composition containing a specific bioactive Lactobacillus fermentum strain grown as a biofilm, with dependent refinements specifying surfaces, targets, and functional activities.
Microbial growth inhibition on a surface using a bioactive Lactobacillus fermentum biofilm
Applying to a surface a microbial growth-inhibiting amount of a composition comprising a bioactive Lactobacillus fermentum strain having an Accession No. PTA-122195 grown as a biofilm.
Methicillin-resistant Staphylococcus aureus growth inhibition
Inhibiting the growth of methicillin-resistant Staphylococcus aureus (MRSA).
Application to skin
Applying the method of inhibiting microbial growth to a surface that is skin.
Skin barrier function enhancement
Enhancing skin barrier function.
PPAR agonist activity
The composition functions as an agonist of PPAR.
Composition comprising alcohol
Including alcohol in the composition.
Overall, the claim coverage centers on delivering a microbial growth-inhibiting composition comprising a specific bioactive Lactobacillus fermentum (Accession No. PTA-122195) biofilm to inhibit microbial growth on a surface, with dependent embodiments narrowing the target to MRSA, limiting the surface to skin, adding skin barrier function enhancement, and specifying PPAR agonist activity and alcohol as a component.
Stated Advantages
Inhibits microbial growth on a surface.
Inhibits pathogenic biofilm growth, adhesion, and detachment while promoting commensal Staphylococcus epidermidis growth.
Enhances skin barrier function, including upregulating filaggrin.
Modulates innate immunity by increasing beta-defensins including HBD-1, HBD-2, and HBD-3.
May act as PPAR agonists, including PPAR-alpha, PPAR-beta/delta, and PPAR-gamma.
Documented Applications
Treatment of dermatological disorders using microbiome-centered therapeutic and cosmetic compositions applied to skin and associated barrier disorders.
Use in skin and mucosal barrier disorders.
Inhibition of MRSA growth on a surface, including within the context of skin application.
Interested in licensing this patent?